clinical response with sunitinib therapy in the treatment of anaplastic thyroid cancer临床反应与舒尼替疗法治疗未分化甲状腺癌.pdfVIP

Journal of Cancer Therapy, 2012, 3, 132-136 /10.4236/jct.2012.32018 Published Online April 2012 (http://www.SciRP.org/journal/jct) Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer 1 2 3 3 2 Kenneth M. Wong , Theodore Scott Nowicki , Carmelo Puccio , Tauseef Ahmed , Raj Tiwari , 2 4 Jan Geliebter , Augustine Moscatello 1Department of Otolaryngology—Head and Neck Surgery, New York Eye and Ear Infirmary, New York, USA; 2Department of Microbiology and Immunology, New York Medical College, Valhalla, USA; 3Department of Medical Oncology, Westchester Medical Center, Valhalla, USA; 4Department of Otolaryngology—Head and Neck Surgery, Westchester Medical Center, Valhalla, USA. Email: kwong@ th st th Received February 28 , 2012; revised March 31 , 2012; accepted April 15 , 2012 ABSTRACT Background: Anaplastic thyroid cancer (ATC), while rare, carries a uniformly poor prognosis. Current treatment in- cludes surgery when possible, radiotherapy, and chemotherapy. Multiple chemotherapeutic agents are in the process of clinical testing, and promising agents include those in the tyrosine kinase inhibitor family. Our patient represents a novel case of ATC treated with sunitinib, one such tyrosine kinase inhibitor. Methods/Results: We utilized the experi- mental sunitinib in conjunction with radiation therapy to treat a patient with aggressive ATC in whom curative resection was unable to be achieved due to carotid sheath and tracheal involvement. The patient had marked clinical response and sustained stable disease for 8 months, which coincides with reported data regarding sunitinib to treat other thyroid ma- lign